The family of interferon (IFN) proteins has now more than reached the potential envisioned
by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical …

The onset of multiple sclerosis (MS) in childhood poses diagnostic and therapeutic
challenges, particularly if the symptoms of the first demyelinating event resemble acute …

Cognitive impairment is common in multiple sclerosis (MS), occurring at all stages of the
disease, and can be a major source of vocational disability, social impairment, and …

Objective To investigate the impact of interferon‐beta (IFNβ) on disease progression in
relapsing‐remitting multiple sclerosis patients. Methods A cohort of 1,504 relapsing …

Natalizumab is a new treatment option for patients with active relapsing-remitting multiple
sclerosis. In phase III studies, natalizumab was highly effective and well tolerated; however …

Objective To report the relationship between disease activity and health‐related quality of
life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab. Methods HRQoL …

Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis
(RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin. In a Phase 3 …

The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon
beta (IFN) while on this therapy for multiple sclerosis (MS) is assessed. On the basis of Class …

Studies in adult patients with multiple sclerosis (MS) suggest significant benefit of early
treatment initiation. However, there are no approved therapies for children and adolescents …

Natalizumab (Tysabri®) was the first adhesion molecule antagonist to make it into clinical
trial for patients with multiple sclerosis (MS) and other inflammatory disorders. Natalizumab …